Dr. Todd T. Kobayashi, MD

Dr. Kobayashi practices at CTA Pathology in Beaverton, Oregon.

Dr. Kobayashi's NPI, 1871582023, was assigned on October 20, 2005. Dr. Kobayashi graduated from Uniformed Services UHS Fe Hebert School of Med in 1996. Dr. Kobayashi holds Colorado license DR.0055860.

Dr. Kobayashi's primary practice is CTA Pathology, at 9750 Sw Nimbus Ave, Beaverton, OR 97008. The practice phone is (503) 906-7300.

Dr. Kobayashi's primary practice is CTA Pathology in Beaverton, Oregon. Dr. Kobayashi is also affiliated with University Hospital. The medical group on file is CTA Pathology. Dmand AI also links Dr. Kobayashi to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Kobayashi's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kobayashi practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Kobayashi's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dmand AI has Dr. Kobayashi's licenses on file in 3 states: Colorado, Indiana and Oregon.

CMS data shows 6,271 Medicare services from Dr. Kobayashi across 17 procedure codes in 2024, for 2,446 Medicare patients. Medicare paid $336,099 for them. Every service was in an office.

CMS counts 2,446 Medicare patients who saw Dr. Kobayashi in 2024. The largest group is 65 to 74, with 1,222 patients. 67% of them have high cholesterol, and 58% have high blood pressure. 3% are also on Medicaid. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kobayashi's median patient age at 73, with 49% women.

In 2024, Dr. Kobayashi wrote 863 Medicare Part D claims for 334 patients. 84% of them were for generic drugs. CMS names the drug for 712 of them, across 22 drugs with 11 or more claims each, at $477,909 in total drug cost. In 2023, CMS named 849 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kobayashi for performance year 2024, reported as part of a group. Dr. Kobayashi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 777 procedures of removal of skin lesions by Dr. Kobayashi, more than 91% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Kobayashi, published from 2014 to 2024. 2015 was the busiest year, with 5. The most frequent topics are Diagnosis, Differential, Skin Neoplasms and Biopsy. Dr. Kobayashi has published most often in J Cutan Pathol. Dr. Kobayashi's most frequent co-authors are Casey D. Bowen, MD, Thomas Marshall Beachkofsky, MD and Chad M. Hivnor, MD.

CMS Open Payments shows 135 general payments to Dr. Kobayashi from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Amgen Inc. paid the most, $937.

Dr. Kobayashi graduated from Uniformed Services UHS Fe Hebert School of Med in 1996.